151 related articles for article (PubMed ID: 24900747)
1. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S
ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
[TBL] [Abstract][Full Text] [Related]
3. Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
Yu M; Lizarzaburu M; Motani A; Fu Z; Du X; Liu JJ; Jiao X; Lai S; Fan P; Fu A; Liu Q; Murakoshi M; Nara F; Oda K; Okuyama R; Reagan JD; Watanabe N; Yamazaki M; Xiong Y; Zhang Y; Zhuang R; Lin DC; Houze JB; Medina JC; Li L
ACS Med Chem Lett; 2013 Sep; 4(9):829-34. PubMed ID: 24900757
[TBL] [Abstract][Full Text] [Related]
4. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
[TBL] [Abstract][Full Text] [Related]
5. GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling.
Wang J; Carrillo JJ; Lin HV
PLoS One; 2016; 11(4):e0154452. PubMed ID: 27104960
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.
Guo L; Parker DL; Zang Y; Sweis RF; Liu W; Sherer EC; Buist N; Terebetski J; Kelly T; Bugianesi R; Priest BT; Dingley KH; Li X; Mitelman S; Salituro G; Trujillo ME; Pachanski M; Kirkland M; Powles MA; Eiermann GJ; Feng Y; Shang J; Howard AD; Ujjainwalla F; Sinz CJ; Debenham JS; Edmondson SD; Nargund RP; Hagmann WK; Li D
ACS Med Chem Lett; 2016 Dec; 7(12):1107-1111. PubMed ID: 27994747
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
8. The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent.
Al-Amily IM; Dunér P; Groop L; Salehi A
Pflugers Arch; 2019 Apr; 471(4):633-645. PubMed ID: 30767071
[TBL] [Abstract][Full Text] [Related]
9. Discovery and pharmacological effects of a novel GPR142 antagonist.
Murakoshi M; Kuwabara H; Nagasaki M; Xiong YM; Reagan JD; Maeda H; Nara F
J Recept Signal Transduct Res; 2017 Jun; 37(3):290-296. PubMed ID: 27807998
[TBL] [Abstract][Full Text] [Related]
10. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.
Lin HV; Efanov AM; Fang X; Beavers LS; Wang X; Wang J; Gonzalez Valcarcel IC; Ma T
PLoS One; 2016; 11(6):e0157298. PubMed ID: 27322810
[TBL] [Abstract][Full Text] [Related]
11. GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function.
Lin HV; Wang J; Wang J; Li W; Wang X; Alston JT; Thomas MK; Briere DA; Syed SK; Efanov AM
Mol Metab; 2018 May; 11():205-211. PubMed ID: 29506910
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
[TBL] [Abstract][Full Text] [Related]
13. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
15. Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice.
Ueda Y; Iwakura H; Bando M; Doi A; Ariyasu H; Inaba H; Morita S; Akamizu T
PLoS One; 2018; 13(6):e0198762. PubMed ID: 29889885
[TBL] [Abstract][Full Text] [Related]
16. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
19. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.
Liu LZ; Ma T; Zhou J; Long Hu Z; Jun Zhang X; Zhen Zhang H; Zeng M; Liu J; Li L; Jiang Y; Zou Z; Wang F; Zhang L; Xu J; Wang J; Xiao F; Fang X; Zou H; Efanov AM; Thomas MK; Lin HV; Chen J
Bioorg Med Chem Lett; 2020 Mar; 30(5):126857. PubMed ID: 31982234
[TBL] [Abstract][Full Text] [Related]
20. Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes.
Kaushik AC; Kumar S; Wei DQ; Sahi S
Front Chem; 2018; 6():23. PubMed ID: 29492402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
